Synthorx Stock Price - THOR

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Synthorx Inc THOR NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.38 -3.0% 12.30 13.09 12.20 12.51 12.68 18:00:57
Bid Price Ask Price Spread Spread % News
12.00 20.52 8.52 41.52% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
784 88,984 $ 12.56 $ 1,117,678 77,016 11.00 - 23.5259
Last Trade Time Type Quantity Stock Price Currency
15:59:55 16 $ 12.30 USD

Synthorx Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 396.87M 32.27M $ -56.61M -18.11 - 31.54M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 8.00 2.30%

more financials information »

Synthorx News

Loading Messages....

Latest THOR Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical THOR Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week12.2414.5212.0812.8464,4400.060.49%
1 Month17.3520.1512.0114.0285,874-5.05-29.11%
3 Months16.3420.7512.0115.7560,030-4.04-24.72%
6 Months17.3620.7511.5615.3066,708-5.06-29.15%
1 Year15.4023.525911.0016.5993,755-3.10-20.13%
3 Years15.4023.525911.0016.5993,755-3.10-20.13%
5 Years15.4023.525911.0016.5993,755-3.10-20.13%

Synthorx Description

Synthorx Inc is a biopharmaceutical company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. The company through its platform technology expands the genetic code by adding a new DNA base pair. Its lead product candidate includes THOR-707 a variant of IL-2 designed to kill tumor cells. It uses the Expanded Genetic Alphabet platform technology to develop cytokine Synthorins. It has designed cytokine Synthorin programs, including IL-2, IL-10 and IL-15, for the treatment of cancer, and another IL-2 Synthorin program for the treatment of autoimmune disorders.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.